Search
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Tubocurarine
go.drugbank.com/drugs/DB01199ApprovedWithdrawn[A216038] Tubocurarine's clinical use was limited by its relatively long duration of action (30-60 minutes)[A216038] and a number of significant side effects. … [A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10990ApprovedHaemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemoph...
Cholestyramine
go.drugbank.com/drugs/DB01432ApprovedInvestigationalCholestyramine resin is quite hydrophilic, but insoluble in water.
Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedIt has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Alanine
go.drugbank.com/drugs/DB00160ApprovedInvestigationalNutraceuticalIt is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.
Alemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigational[L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).